EP4461361A3 - Use of vitamin composition in preparing drug for preventing, treating, or delaying alzheimer's disease - Google Patents

Use of vitamin composition in preparing drug for preventing, treating, or delaying alzheimer's disease Download PDF

Info

Publication number
EP4461361A3
EP4461361A3 EP24189913.7A EP24189913A EP4461361A3 EP 4461361 A3 EP4461361 A3 EP 4461361A3 EP 24189913 A EP24189913 A EP 24189913A EP 4461361 A3 EP4461361 A3 EP 4461361A3
Authority
EP
European Patent Office
Prior art keywords
disease
treating
preventing
preparing drug
vitamin composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP24189913.7A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4461361A2 (en
Inventor
Mingdong Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zensun Shanghai Science and Technology Ltd
Original Assignee
Zensun Shanghai Science and Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zensun Shanghai Science and Technology Ltd filed Critical Zensun Shanghai Science and Technology Ltd
Publication of EP4461361A2 publication Critical patent/EP4461361A2/en
Publication of EP4461361A3 publication Critical patent/EP4461361A3/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP24189913.7A 2017-03-07 2018-02-24 Use of vitamin composition in preparing drug for preventing, treating, or delaying alzheimer's disease Withdrawn EP4461361A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710131111.XA CN108567792A (zh) 2017-03-07 2017-03-07 一种治疗阿尔茨海默病的复合维生素组合物
PCT/CN2018/077107 WO2018161808A1 (zh) 2017-03-07 2018-02-24 维生素组合物在制备用于预防、治疗或延迟阿尔茨海默病的药物中的用途
EP18763903.4A EP3593805B1 (en) 2017-03-07 2018-02-24 Use of vitamin composition in preparing drug for preventing, treating, or delaying alzheimer's disease

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP18763903.4A Division EP3593805B1 (en) 2017-03-07 2018-02-24 Use of vitamin composition in preparing drug for preventing, treating, or delaying alzheimer's disease

Publications (2)

Publication Number Publication Date
EP4461361A2 EP4461361A2 (en) 2024-11-13
EP4461361A3 true EP4461361A3 (en) 2025-01-01

Family

ID=63448062

Family Applications (2)

Application Number Title Priority Date Filing Date
EP24189913.7A Withdrawn EP4461361A3 (en) 2017-03-07 2018-02-24 Use of vitamin composition in preparing drug for preventing, treating, or delaying alzheimer's disease
EP18763903.4A Active EP3593805B1 (en) 2017-03-07 2018-02-24 Use of vitamin composition in preparing drug for preventing, treating, or delaying alzheimer's disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP18763903.4A Active EP3593805B1 (en) 2017-03-07 2018-02-24 Use of vitamin composition in preparing drug for preventing, treating, or delaying alzheimer's disease

Country Status (9)

Country Link
US (2) US11464797B2 (enExample)
EP (2) EP4461361A3 (enExample)
JP (3) JP7169285B2 (enExample)
CN (2) CN108567792A (enExample)
AU (2) AU2018229920B2 (enExample)
BR (1) BR112019018652A2 (enExample)
CA (1) CA3054972A1 (enExample)
ES (1) ES2989651T3 (enExample)
WO (1) WO2018161808A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7442874B2 (ja) * 2019-08-02 2024-03-05 シャンハイ、レイジング、ファーマシューティカル、カンパニー、リミテッド アルツハイマー病における標的としてのｔｐｋの使用
KR102275981B1 (ko) * 2020-03-31 2021-07-13 고려은단주식회사 섬쑥부쟁이 추출물과 비타민 b 복합체의 혼합물을 포함하는 인지기능 개선용 조성물
AU2022464309A1 (en) * 2022-06-22 2025-01-23 Biomedical Research Group Inc. Prophylactic drug and therapeutic drug for diabetes-associated dementia
CN119055674B (zh) * 2024-11-06 2025-02-18 中国医学科学院北京协和医院 一种可改善认知的组合物及其在阿尔茨海默病防治中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160129058A1 (en) * 2007-08-03 2016-05-12 Shaklee Corporation Nutritional supplement system
CA2989214A1 (en) * 2015-06-12 2016-12-15 Zensun (Shanghai) Science & Technology, Co., Ltd. Use of composition of multivitamin in preparing drug for stimulating gastrointestinal system motility
EP3545960A1 (en) * 2016-11-23 2019-10-02 Zensun (Shanghai) Science & Technology, Co., Ltd. Composite vitamin composition promoting gastrointestinal system motility

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5626884A (en) 1995-08-18 1997-05-06 Lockett; Curtis G. Treatment of sickle cell disease
DE69930746T2 (de) 1998-06-10 2007-03-15 Crum, Albert B. Vorbeugender und therapeutischer nahrungsmittelzusatz zur schaffung/erhaltung einer die gesundheit schützenden darmmikroflora und zur stärkung des immunsystems
WO2003082339A1 (en) 2002-03-22 2003-10-09 Doc's Guide, Inc. Multivitamin and mineral nutritional supplement
CA2583972A1 (en) 2004-10-14 2006-10-19 Adventures Plus Pty Ltd A method for the treatment of gastrointestinal and other disorders with an admixture of vitamins and minerals
US20110275591A1 (en) * 2004-12-01 2011-11-10 Concourse Health Sciences Llc Cocktail for modulation of alzheimer's disease
US20060148727A1 (en) * 2004-12-01 2006-07-06 Curt Hendrix Folate based composition for neurological and cognitive applications
NZ582329A (en) * 2007-06-26 2012-09-28 Nutricia Nv Improving memory in subjects with mini-mental state examination of 24-26
JP4206428B1 (ja) * 2008-06-09 2009-01-14 正樹 今川 認知症を処置するための組成物及びその利用
KR20110004691A (ko) * 2009-07-08 2011-01-14 대한민국(농촌진흥청장) 뇌기능 개선효과를 가지는 붉나무 추출물을 포함하는 약학조성물 및 건강식품조성물
EP2554057A4 (en) * 2010-03-31 2013-12-18 Vegenat S A ENERAL OR ORAL FOOD PRODUCT SPECIALLY FOR NUTRITION, PREVENTION AND MITIGATION OF NEUROLOGICAL OR NEURODEGENERATIVE ALTERATIONS OR COGNITIVE DISORDERS
US8563609B2 (en) * 2010-05-13 2013-10-22 Nitromega Corp. Nitro fatty acids - neuroprotection and/or inhibition of cognitive decline
WO2012012682A2 (en) 2010-07-22 2012-01-26 Zishan Haroon Methods of treating or ameliorating diseases and enhancing performance comprising the use of a magnetic dipole stabilized solution
KR20130015932A (ko) * 2011-08-05 2013-02-14 연세대학교 산학협력단 저용량의 치아졸리딘다이온을 포함하는 알츠하이머 병 치료용 약학조성물
WO2013066151A1 (en) * 2011-10-31 2013-05-10 N.V. Nutricia Improving recognition
BR112014020177A8 (pt) * 2012-03-02 2021-10-19 Nutricia Nv Uso de uma composição para a fabricação de um produto para diminuir, prevenir ou reverter a conectividade cerebral funcional prejudicada e/ou organização da rede cerebral prejudicada
EP2882304A1 (en) * 2012-08-07 2015-06-17 Buck Institute For Research On Aging Multi-component formulation for improving neurological function
WO2014026161A1 (en) * 2012-08-10 2014-02-13 Aquavit Pharmaceuticals, Inc. Vitamin supplement compositions for injection
CN104337813A (zh) 2013-07-23 2015-02-11 上海泽生科技开发有限公司 使用维生素b组合物促进胃肠系统动力的方法
CN104256652A (zh) 2014-10-08 2015-01-07 李明刚 一种口服复合维生素纳米脂质体
CN104922164B (zh) * 2014-12-12 2020-06-02 中国医科大学 一种治疗阿尔茨海默病的药物复合制剂
CN104856048A (zh) 2015-06-18 2015-08-26 安徽医联大成医药科技有限公司 一种促进肠胃蠕动的食品配方及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160129058A1 (en) * 2007-08-03 2016-05-12 Shaklee Corporation Nutritional supplement system
CA2989214A1 (en) * 2015-06-12 2016-12-15 Zensun (Shanghai) Science & Technology, Co., Ltd. Use of composition of multivitamin in preparing drug for stimulating gastrointestinal system motility
EP3545960A1 (en) * 2016-11-23 2019-10-02 Zensun (Shanghai) Science & Technology, Co., Ltd. Composite vitamin composition promoting gastrointestinal system motility

Also Published As

Publication number Publication date
JP2020509072A (ja) 2020-03-26
US20200030358A1 (en) 2020-01-30
US20230248756A1 (en) 2023-08-10
JP2023011769A (ja) 2023-01-24
CA3054972A1 (en) 2018-09-13
AU2024202678A1 (en) 2024-05-16
JP2025024089A (ja) 2025-02-19
CN108567792A (zh) 2018-09-25
JP7169285B2 (ja) 2022-11-10
EP3593805A1 (en) 2020-01-15
US11464797B2 (en) 2022-10-11
BR112019018652A2 (pt) 2020-04-07
CN110520135A (zh) 2019-11-29
ES2989651T3 (es) 2024-11-27
EP4461361A2 (en) 2024-11-13
EP3593805A4 (en) 2020-10-07
WO2018161808A1 (zh) 2018-09-13
AU2018229920A1 (en) 2019-10-03
AU2018229920B2 (en) 2024-02-08
EP3593805B1 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
USD843592S1 (en) Ejaculation promotion apparatus
WO2015165413A8 (zh) 一种新型的稳定型抗体药物耦联物及其制备方法和用途
ZA202103074B (en) Formulation based on medicinal plant, or part or extract thereof, use of the formulation and product including said formulation
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MY190855A (en) Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
EP3398948A3 (en) 2,4,6,7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
NZ725480A (en) Anti-ptk7 antibody-drug conjugates
EP3536168A3 (en) Probiotic formulations and methods for use
EP4527467A3 (en) Pharmaceutical formulations
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
WO2014180889A8 (en) Methods and compositions for the treatment of cancer
IL276952A (en) History of 4,2-diaminoquinazolines and their medicinal uses
EP4289820A3 (en) Compounds for use in treating alzheimer's disease in apoe4+/+ patients
MY209101A (en) Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof
PH12021550413A1 (en) Vitamin d pediatric dosage forms, methods of making and using
EP4461361A3 (en) Use of vitamin composition in preparing drug for preventing, treating, or delaying alzheimer's disease
WO2018187331A8 (en) Macrocyclic compound and uses thereof
PH12020550125A1 (en) Crystalline forms of 3-substituted 1,2,4-oxadiazole
WO2017121646A8 (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
EP4339192A3 (en) Compounds and compositions for the treatment of cancer
EP4342461A3 (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
CA3010981A1 (en) Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 3593805

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61P0025280000

Ipc: A61K0031714000

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/28 20060101ALI20241127BHEP

Ipc: A61K 31/355 20060101ALI20241127BHEP

Ipc: A61K 31/375 20060101ALI20241127BHEP

Ipc: A61K 31/4415 20060101ALI20241127BHEP

Ipc: A61K 31/714 20060101AFI20241127BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20250702